WHO Prequalification Programme
WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

KOZENIS Dispersible Tablets[1]

Tafenoquine (as succinate) 50 mg dispersible tablets

KOZENIS Dispersible Tablets was submitted in 2024 by GlaxoSmithKline Australia Pty Ltd. to be considered for prequalification and subsequently accepted for the WHO list of prequalified products for the treatment of malaria on 02 December 2024.

Information on the site(s) involved in the manufacture of the product and the API is available at the products listing information: https://extranet.who.int/prequal/medicines/ma204

The "Procedure for prequalification of pharmaceutical products[2]" defines specific evaluation mechanisms for products approved by regulatory authorities, which apply similar stringent standards for quality, safety and efficacy as those required by WHO.

The prequalification of this product by the WHO Prequalification Team: Medicines (PQTm), is based on the approval by the Australian "Therapeutic Goods Administration", (TGA, https://www.tga.gov.au/), in line with the "Guidelines on submission of documentation for prequalification of finished pharmaceutical products approved by stringent regulatory authorities" [3].

Hence, no assessment of the data underlying this approval has been undertaken within the WHO Prequalification Programme.

However, according to the SRA guideline WHO may request additional data when considered necessary for the safe use of the product in regions relevant for prequalified products and such information may be included in the WHOPAR as a separate piece of information. In order to safeguard product quality throughout its entire intended shelf-life in hot and very humid areas, stability studies under the conditions defined for Climatic Zones IVb have been requested from the Applicant[4].

Based on the submitted stability data WHO PQTm considers the following storage condition appropriate for the product when distributed in regions with zone III, IVa and IVb climatic conditions, based on available stability information:

[1] Trade names are not prequalified by WHO. This is the National Medicines Regulatory Authority's responsibility. Throughout this WHOPAR the proprietary name is given as an example only.

[2] https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs961-annex10-who-procedure-prequalification.pdf?sfvrsn=85029f47_2

[3] https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs986-annex5.pdf?sfvrsn=8aae767d_2

[4] https://extranet.who.int/prequal/sites/default/files/document_files/48%20Stability%20data%20SRA%20FPPs_March2016_newtempl.pdf

- Do not store above 30°C. Store in the original package to protect from moisture.
- The shelf-life at this storage condition is 24 months.

This WHOPAR refers to the information available at the approving stringent regulatory authority's website resulting from the assessment of the quality, efficacy and safety as well as steps taken after approval.

(https://www.tga.gov.au/resources/auspar/auspar-kozenis AUST R 350774)

For details on the uses of this product, for relevant efficacy and safety information, see the Australian Product Information and the Consumer Medicine Information.
(https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=Kozenis&r=/)

KOZENIS Dispersible Tablets contains tafenoquine succinate.

Its WHO recommended use is, in combination with chloroquine, for the radical cure (prevention of relapse) of *Plasmodium vivax* (*P. vivax*) malaria.

Summary of Prequalification Status for KOZENIS Dispersible Tablets

Initial acceptance	**Date**	**Outcome**
Status on PQ list	02 December 2024	listed
Quality	November 2024	MR
PQ: prequalification MR: meets requirements		

The table represents the status of relevant completed activities only.